Fulvestrant-Teva 250mg/5ml, Injektionslösung in einer Fertigspritze

7680664700022 CH-66470 Injektionslösung
Fulvestrant-Teva 250mg/5ml, Injektionslösung in einer Fertigspritze
Fulvestrant-Teva 250mg/5ml, Injektionslösung in einer Fertigspritze
1 / 2
google

Article details

Package size
2
Selling units
2
Measure
Fertigspritze(n)
Galenic form
Injektionslösung
Galenic group
Injektion/Infusion

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Summary of Product Characteristics
Allemand
25/09/2024
Summary of Product Characteristics
Français
25/09/2024
Summary of Product Characteristics
Italien
25/09/2024

Detailed composition

Substance Quantity Type Category
(N/A)
250.0 MG Substance Wirkstoff (Principe actif)
(N/A)
500.0 MG Substance HBESI
(N/A)
500.0 MG Substance HBESI
(N/A)
750.0 MG Substance HBESI
(N/A)
- Substance HNIDK
(N/A)
12.16 PVV Substance HBESI

Reimbursement information

Public price
CHF 329.05
Specialties list
Yes
Generic
Yes

Reimbursement limitation

SL addition date: 01/01/2021

Authorization holder

Teva Pharma AG

4051 Basel

Authorization information

Swissmedic authorization number
66470
Drug name
Fulvestrant-Teva, Injektionslösung in einer Fertigspritze
Galenic form
LSPA
ATC Code
L02BA03
Authorization status
Z
Dispensing category
B
First authorization
27/07/2017
Authorization expiration date
31/12/9999
IT Number
07.16.2.
Domain
Human medicine
Field of application
Zytostatikum

Package details

Description (FR)
FULVESTRANT Teva sol inj 250 mg/5ml ser pré 2 pce
Description (DE)
FULVESTRANT Teva Inj Lös 250 mg/5ml Fertspr 2 Stk
Market launch
27/07/2017
Narcotic (BTM)
No

Original drug

Faslodex, Injektionslösung
GTIN: 7680567780121
CHF 379.80
View original

Other package sizes (1)

None
1 FESP
GTIN: None
Not in V1